Cat. No.: HY-B1203

Fludrocortisone

(Synonyms: 9α-Fludrocortisone; 9α-Fluorcortisol)

Customer Review

Based on 1 Customer Validation

Fludrocortisone (9α-Fludrocortisone) is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

For research use only. We do not sell to patients.

Purity: 98.99%
CAS No.: 127-31-1
Formula: C₂₁H₂₉FO₅
Molecular Weight:380.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fludrocortisone Chemical Structure

CAS No.: 127-31-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Fludrocortisone (0.01-10 μg/μL; 12 h) is non-cytotoxic to MIO-M1, ARPE19, and 661W human retinal cell lines at concentrations up to 1 μg/μL, with reduced viability only seen at 10 μg/μL in MIO-M1 and 661W cells^[1].
Fludrocortisone (1 μg/μL; 12 h) potently suppresses IL-1β- and TNF-α-induced CCL2, IL-6, and IL-8 mRNA expression in MIO-M1 human Müller glial cells^[1].
Fludrocortisone (1 μM; 24 h) increases mineralocorticoid receptor
(MR) gene expression in AHPs without altering glucocorticoid receptor (GR) expression^[2].
Fludrocortisone (0.5-2 μM; 24 h) promotes survival, proliferation, and reduces apoptosis in growth factor-deprived AHPs, with 1 μM being the optimal concentration^[2].
Fludrocortisone (1 μM) activates cAMP/PKA/CREB signaling in AHPs, which is required for its pro-survival and pro-proliferative effects^[2].
Fludrocortisone (1 μM) activates PI3K/Akt and mTOR/p70S6K signaling, and inactivates GSK-3β, which is required for its protective effects in growth factor-deprived AHPs^[2].
Fludrocortisone (1 μM) protects AHPs from Aβ_1-42-induced toxicity by promoting survival, proliferation, reducing apoptosis, restoring Akt/GSK-3β phosphorylation, and blocking Tau hyperphosphorylation^[2].
Fludrocortisone (4-6 h) stimulates Epo, HIF2α, HIF1α, and PHD2 mRNA expression in microdissected rat nephron segments and mouse kidney nephron segments and peritubular cells, with significant increases relative to basal conditions^[5].
Fludrocortisone (6 h, 72 h) significantly increases Epo protein expression in rat renal cortex but not in rat liver, relative to basal conditions^[5].
Fludrocortisone (4-6 h) stimulates Epo protein production in mouse MAL, CCD, and OMCD, with specific upregulation in type A intercalated cells of the collecting ducts, and effects diminish to basal levels by 72 h^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human MIO-M1 Müller glial cells, ARPE19 retinal pigment epithelial cells, 661W cone photoreceptor-like cells
Concentration:

0.01-10 μg/μL
Incubation Time:

12 h
Result:

Did not significantly alter cell viability in ARPE19 cells at all tested concentrations. Showed unchanged viability in MIO-M1 and 661W cells at 0.01, 0.1, and 1 μg/μL; caused a slight but statistically significant reduction in viability only at the highest concentration of 10 μg/μL in MIO-M1 and 661W cells.

Real Time qPCR^[1]

Cell Line:

human MIO-M1 Müller glial cells
Concentration:

1 μg/μL
Incubation Time:

12 h (co-incubated with IL-1β stimulation)
Result:

Completely abrogated IL-1β-induced significant increases in CCL2, IL-6, and IL-8 mRNA expression, suppressing expression to near baseline levels.

Real Time qPCR^[1]

Cell Line:

human MIO-M1 Müller glial cells
Concentration:

1 μg/μL
Incubation Time:

12 h (co-incubated with TNF-α stimulation)
Result:

Sharply reduced TNF-α-induced significant increases in CCL2, IL-6, and IL-8 mRNA expression, suppressing expression to near baseline levels.

Real Time qPCR^[1]

Cell Line:

Human MIO-M1 Müller glial cells
Concentration:

1 μg/μL
Incubation Time:

12 h (co-incubated with IL-1β stimulation)
Result:

Had its suppressive effect on IL-1β-induced CCL2, IL-6, and IL-8 expression completely abrogated by co-incubation with glucocorticoid receptor antagonist RU486.

Real Time qPCR^[2]

Cell Line:

Adult rat hippocampal progenitor cells (AHPs)
Concentration:

1 μM
Incubation Time:

24 h
Result:

Strongly increased mineralocorticoid receptor (MR) gene expression; showed no significant change in glucocorticoid receptor (GR) gene expression.

Cell Viability Assay^[2]

Cell Line:

Adult rat hippocampal progenitor cells (AHPs)
Concentration:

0.01, 0.1, 0.5, 1, 2 μM
Incubation Time:

24 h
Result:

Progressively increased cell survival and proliferation at 0.5, 1, and 2 μM; strongly reduced serum starvation-induced apoptosis (via decreased caspase-3 activity) at 0.5, 1, and 2 μM; identified 1 μM as the optimal concentration for subsequent experiments.

Western Blot Analysis^[2]

Cell Line:

adult rat hippocampal progenitor cells (AHPs)
Concentration:

1 μM (cAMP/CREB phosphorylation assays); 1 μM (functional validation with KT5720)
Incubation Time:

5, 15, 30, 60, 90 min (cAMP/CREB phosphorylation assays); 24 h (functional validation with KT5720)
Result:

Increased intracellular cAMP levels, with a peak at 15 min and sustained elevation through 90 min; promoted CREB phosphorylation (Ser133), peaking at 15-30 min and returning to near basal levels by 90 min; had induced survival and proliferation reduced by co-treatment with PKA inhibitor KT5720.

Western Blot Analysis^[2]

Cell Line:

adult rat hippocampal progenitor cells (AHPs)
Concentration:

1 μM (phosphorylation assays); 1 μM (functional validation with wortmannin/rapamycin)
Incubation Time:

5, 15, 30, 60, 90 min (phosphorylation assays); 24 h (functional validation with wortmannin/rapamycin)
Result:

Induced time-dependent phosphorylation of Akt (peaking at 30 min, sustained through 90 min), GSK-3β (sustained elevation from 5 to 90 min), and p70S6K (progressive elevation through 90 min); had induced survival, proliferation, and antiapoptotic effects reduced by co-treatment with Wortmannin or Rapamycin.

In Vivo

Fludrocortisone (1 μg/μL; intravitreal injection (3 μL); single dose) exerts neuroprotective effects in a mouse photo-oxidative retinal degeneration model, preserving retinal structure and function, reducing photoreceptor apoptosis, and inhibiting macrophage infiltration^[1].
Fludrocortisone (1.5 mg/kg; i.p.; twice on Days 4 and 5 of pregnancy) modulates uterine receptivity in pregnant BALB/c mice by upregulating LIF, HB-EGF, Msx.1, and miRNA Let-7a, and activating the ERK1/2-mTOR pathway without altering MUC1 or miRNA 223-3p expression^[4].
Fludrocortisone (1.5 mg/kg; i.p.; twice on Days 4 and 5 of pregnancy) co-administered with PP242 (30 mg/kg) reverses PP242-induced MUC1 upregulation and restores upregulation of key uterine receptivity genes (LIF, HB-EGF, Msx.1, miRNA Let-7a) in pregnant BALB/c mice^[4].
Fludrocortisone (2.5 mg/100 g BW/day; i.p.; daily) stimulates renal Epo mRNA expression (peak at 4 hours) and Epo protein expression (at 6 and 72 hours) in male Sprague Dawley rats, with a statistically significant increase in plasma Epo concentration at 6 hours post-administration^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (60 post-natal days old)^[1]
Dosage:

1 μg/μL
Administration:

intravitreal injection; single dose
Result:

Preserved outer nuclear layer thickness at locations 1-2 mm and 2-3 mm superior to the optic nerve compared to controls; Achieved significantly higher a-wave and b-wave ERG responses; Reduced the number of TUNEL+ apoptotic photoreceptors significantly compared to vehicle-treated mice; Decreased the number of subretinal IBA1+ macrophages significantly compared to vehicle-treated mice.

Animal Model:

BALB/c (8-week-old virgin female; pregnancy model, estrous induced, mated with fertile males, vaginal plug confirmed)^[4]
Dosage:

1.5 mg/kg
Administration:

i.p.; twice on Days 4 and 5 of pregnancy at 8:00 a.m.
Result:

Did not significantly alter mRNA expression of mucin-1 (MUC1) or miRNA 223-3p; significantly upregulated mRNA expression of leukemia inhibitory factor (LIF), heparin-binding epidermal growth factor (HB-EGF, Msx.1, and miRNA Let-7a; significantly increased phosphorylated ERK1/2 (p-ERK1/2) and phosphorylated mammalian target of rapamycin (p-mTOR) levels; did not change phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1) levels significantly; induced round epithelial cell nuclei, cuboidal endometrial epithelium, no detectable glycoprotein layer on the epithelial surface, a thin continuous basement membrane beneath epithelial cells, and proliferating fibroblast-like stromal cells.

Animal Model:

BALB/c (8-week-old virgin female; pregnancy model, estrous induced, mated with fertile males, vaginal plug confirmed)^[4]
Dosage:

1.5 mg/kg (fludrocortisone); 30 mg/kg (PP242)
Administration:

i.p.; twice on Days 4 and 5 of pregnancy at 8:00 a.m. (fludrocortisone); co-administered with PP242
Result:

Significantly upregulated mRNA expression of LIF, HB-EGF, Msx.1, and miRNA Let-7a compared to PP242-only group; significantly downregulated mRNA expression of MUC1 compared to PP242-only group; did not change miRNA 223-3p expression significantly compared to PP242-only group.

Animal Model:

Sprague Dawley (male)^[5]
Dosage:

2.5 mg/100 g BW/day
Administration:

i.p.; daily
Result:

Increased Epo, HIF2α, and HIF1α mRNA expression in renal cortex at 4 hours post-injection; the stimulating effect disappeared by 72 hours. Increased Epo protein expression in renal cortex at 6 and 72 hours. Increased plasma Epo concentration at 6 hours (statistically significant elevation vs. vehicle), but not at 72 hours. Did not alter Epo mRNA or protein expression in the liver.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 127-31-1
Appearance Solid
Molecular Weight 380.45
Formula C₂₁H₂₉FO₅
Color White to off-white
SMILES

C[C@@]12[C@](C(CO)=O)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Synonyms

9α-Fludrocortisone; 9α-Fluorcortisol
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (262.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6285 mL

13.1423 mL

26.2847 mL

5 mM

0.5257 mL

2.6285 mL

5.2569 mL

10 mM

0.2628 mL

1.3142 mL

2.6285 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Racic T, et al. Anti-inflammatory and neuroprotective properties of the corticosteroid fludrocortisone in retinal degeneration. Exp Eye Res. 2021;212:108765. [Content Brief]

[2]. Gesmundo I, et al. The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors. Front Endocrinol (Lausanne). 2016;7:66. Published 2016 Jun 16. [Content Brief]

[3]. Veazie S, et al, Helfand M. Fludrocortisone for orthostatic hypotension. Cochrane Database Syst Rev. 2021 May 17;5(5):CD012868. [Content Brief]

[4]. Hesam Shariati MB, et al. The effect of fludrocortisone on the uterine receptivity partially mediated by ERK1/2-mTOR pathway. J Cell Physiol. 2019;234(11):20098-20110. [Content Brief]

[5]. Yasuoka Y, et al. Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ducts. Biochem Biophys Res Commun. 2018;503(4):3121-3127. [Content Brief]

[6]. Jaal J, et al. Small Cell Lung Cancer Patient with Profound Hyponatremia and Acute Neurological Symptoms: An Effective Treatment with Fludrocortisone. Case Rep Oncol Med. 2015;2015:286029. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6285 mL	13.1423 mL	26.2847 mL	65.7117 mL
	5 mM	0.5257 mL	2.6285 mL	5.2569 mL	13.1423 mL
	10 mM	0.2628 mL	1.3142 mL	2.6285 mL	6.5712 mL
	15 mM	0.1752 mL	0.8762 mL	1.7523 mL	4.3808 mL
	20 mM	0.1314 mL	0.6571 mL	1.3142 mL	3.2856 mL
	25 mM	0.1051 mL	0.5257 mL	1.0514 mL	2.6285 mL
	30 mM	0.0876 mL	0.4381 mL	0.8762 mL	2.1904 mL
	40 mM	0.0657 mL	0.3286 mL	0.6571 mL	1.6428 mL
	50 mM	0.0526 mL	0.2628 mL	0.5257 mL	1.3142 mL
	60 mM	0.0438 mL	0.2190 mL	0.4381 mL	1.0952 mL
	80 mM	0.0329 mL	0.1643 mL	0.3286 mL	0.8214 mL
	100 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6571 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fludrocortisone

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Chemokine Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Human Hormone Compound Library

Mass Spectrometry Human Metabolite Library

Steroid Hormones Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fludrocortisone Related Classifications

HY-B1203 Related Classifications